Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
6,138,804
-
Number of holders
-
28
-
Total 13F shares, excl. options
-
2,534,934
-
Shares change
-
+625,845
-
Total reported value, excl. options
-
$5,045,318
-
Value change
-
+$1,153,251
-
Put/Call ratio
-
96.25%
-
Number of buys
-
9
-
Number of sells
-
-8
-
Price
-
$1.99
Significant Holders of QUALIGEN THERAPEUTICS, INC. - Common Stock, par value $0.001 per share (QLGN) as of Q2 2021
35 filings reported holding QLGN - QUALIGEN THERAPEUTICS, INC. - Common Stock, par value $0.001 per share as of Q2 2021.
QUALIGEN THERAPEUTICS, INC. - Common Stock, par value $0.001 per share (QLGN) has 28 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 2,534,934 shares
of 6,138,804 outstanding shares and own 41.29% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (1,023,911 shares), BlackRock Inc. (333,405 shares), GEODE CAPITAL MANAGEMENT, LLC (168,702 shares), COMMONWEALTH EQUITY SERVICES, LLC (137,510 shares), RENAISSANCE TECHNOLOGIES LLC (113,911 shares), PRICE T ROWE ASSOCIATES INC /MD/ (107,500 shares), STATE STREET CORP (104,314 shares), QS Investors, LLC (82,000 shares), HighMark Wealth Management LLC (80,094 shares), and PERKINS CAPITAL MANAGEMENT INC (53,304 shares).
This table shows the top 28 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.